Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGIOS PHARMACEUTICALS, INC. Director's Dealing 2015

Feb 11, 2015

31580_dirs_2015-02-11_14af91b4-c28a-428e-bea9-de9dced94d7b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-02-09

Reporting Person: Goddard Glenn (Senior Vice President, Finance)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-02-09 Common stock M 681 $0.6875 Acquired 681 Direct
2015-02-09 Common stock M 14319 $23.10 Acquired 15000 Direct
2015-02-09 Common stock S 15000 $105.81 Disposed 0 Direct
2015-02-11 Common stock M 1513 $23.10 Acquired 1513 Direct
2015-02-11 Common stock S 1513 $120.14 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-02-09 Stock option (right to buy) $0.6875 M 681 Disposed 2021-09-14 Common stock (681) Direct
2015-02-09 Stock option (right to buy) $23.10 M 14319 Disposed 2023-08-27 Common stock (14319) Direct
2015-02-11 Stock option (right to buy) $23.10 M 1513 Disposed 2023-08-27 Common stock (1513) Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $103.51 to $107.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $120.00 to $120.32. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price

F5: This option was granted on September 15, 2011. The shares underlying this option vest as to 25% of the underlying shares on September 15, 2012, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F6: This option was granted on August 28, 2013. The shares underlying this option vest as to 25% of the underlying shares on August 28, 2014, with the remaining 75% vesting in 36 equal monthly installments thereafter.